72 related articles for article (PubMed ID: 24524969)
21. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
22. Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Mouillet G; Nguyen Tan Hon T; Montcuquet P; Maurina T; Almotlak H; Stein U; Montange D; Foubert A; Nerich V; Pivot X; Royer B
Cancer Chemother Pharmacol; 2014 May; 73(5):999-1007. PubMed ID: 24682543
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
24. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
26. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Amato RJ; Flaherty AL; Stepankiw M
Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
[TBL] [Abstract][Full Text] [Related]
28. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
[TBL] [Abstract][Full Text] [Related]
29. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
30. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.
Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V
Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215
[TBL] [Abstract][Full Text] [Related]
31. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
Garcia JA; Hudes GR; Choueiri TK; Stadler WM; Wood LS; Gurtler J; Bhatia S; Joshi A; Hozak RR; Xu Y; Schwartz JD; Thompson JA
Cancer; 2014 Jun; 120(11):1647-55. PubMed ID: 24577874
[TBL] [Abstract][Full Text] [Related]
32. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
33. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
34. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
Stenner-Liewen F; Grünwald V; Greil R; Porta C
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1021-33. PubMed ID: 24024788
[TBL] [Abstract][Full Text] [Related]
35. Temsirolimus: a safety and efficacy review.
Bukowski RM
Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
[TBL] [Abstract][Full Text] [Related]
36. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
[TBL] [Abstract][Full Text] [Related]
37. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
Stenehjem DD; Hahn AW; Gill DM; Albertson D; Gowrishankar B; Merriman J; Agarwal AM; Thodima V; Harrington EB; Au TH; Maughan BL; Houldsworth J; Pal SK; Agarwal N
PLoS One; 2019; 14(1):e0210415. PubMed ID: 30682039
[TBL] [Abstract][Full Text] [Related]
38. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
39. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
40. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]